Key statistics
As of last trade MaxCyte Inc (MYE0:STU) traded at 3.10, 8.39% above its 52-week low of 2.86, set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.12 |
Low | 2.88 |
Bid | 3.08 |
Offer | 3.52 |
Previous close | 2.96 |
Average volume | 0.00 |
---|---|
Shares outstanding | 105.48m |
Free float | 98.76m |
P/E (TTM) | -- |
Market cap | 363.91m USD |
EPS (TTM) | -0.3420 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Announcements
- MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
- MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
- MaxCyte to Participate in Two Upcoming Investor Conferences
- MaxCyte Appoints Cynthia Collins to its Board of Directors
- MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
- MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
- MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
- MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
- MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
- MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
More ▼